A history of chronic morphine exposure during adolescence increases despair-like behaviour and strain-dependently promotes sociability in abstinent adult mice

Behavioural Brain Research

Volumn 243, Issue 1, 2013, Pages 44-52

  Lutz, P E ^a   Reiss, D ^b   Ouagazzal, A M ^b   Kieffer, B L ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Abstinence; Adolescence; Anxiety; Depression; Morphine; Sociability

Indexed keywords

MORPHINE;

ABSTINENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; HEALTH BEHAVIOR; HOPELESSNESS; LOCOMOTION; LONG TERM EXPOSURE; MALE; MOUSE; NONHUMAN; PHYSICAL MOBILITY; PRIORITY JOURNAL; SOCIAL INTERACTION; WEIGHT GAIN;

AGING; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; EMOTIONS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MORPHINE; MORPHINE DEPENDENCE; NARCOTICS; NEUROPSYCHOLOGICAL TESTS; SOCIAL BEHAVIOR; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84872579868     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.12.049     Document Type: Article

References (99)

1. Baler R.D., Volkow N.D. Drug addiction: the neurobiology of disrupted self-control. Trends in Molecular Medicine 2006, 12:559-566.
2. Koob G.F., Le Moal M. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences 2008, 363:3113-3123.
3. Grant B.F., Stinson F.S., Dawson D.A., Chou S.P., Dufour M.C., Compton W., et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry 2004, 61:807-816.
4. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
5. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005, 62:593-602.
6. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., et al. Comorbidity of mental disorders with alcohol and other drug abuse results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990, 264:2511-2518.
7. Grella C.E., Karno M.P., Warda U.S., Niv N., Moore A.A. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addictive Behaviors 2009, 34:498-504.
8. Brewer D.D., Catalano R.F., Haggerty K., Gainey R.R., Fleming C.B. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 1998, 93:73-92.
9. Childress A.R., Ehrman R., McLellan A.T., MacRae J., Natale M., O'Brien C.P. Can induced moods trigger drug-related responses in opiate abuse patients. Journal of Substance Abuse Treatment 1994, 11:17-23.
10. Rounsaville B.J., Kosten T.R., Weissman M.M., Kleber H.D. Prognostic significance of psychopathology in treated opiate addicts. A 2.5-year follow-up study. Archives of General Psychiatry 1986, 43:739-745.
11. Goudemand M. Les états dépressifs 2010, Médecine Sciences Publications, Lavoisier.
12. Aston-Jones G., Harris G.C. Review - brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology 2004, 47(Suppl. 1):167-179.
13. Sakoori K., Murphy N.P. Maintenance of conditioned place preferences and aversion in C57BL6 mice: effects of repeated and drug state testing. Behavioural Brain Research 2005, 160:34-43.
14. Wikler A., Pescor F.T. Persistence of relapse-tendencies of rats previously made physically dependent on morphine. Psychopharmacologia 1970, 16:375-384.
15. Harris G.C., Aston-Jones G. Altered motivation and learning following opiate withdrawal: evidence for prolonged dysregulation of reward processing. Neuropsychopharmacology 2003, 28:865-871.
16. Lieblich I., Yirmiya R., Liebeskind J.C. Intake of and preference for sweet solutions are attenuated in morphine-withdrawn rats. Behavioral Neuroscience 1991, 105:965-970.
17. Zhang D., Zhou X., Wang X., Xiang X., Chen H., Hao W. Morphine withdrawal decreases responding reinforced by sucrose self-administration in progressive ratio. Addiction Biology 2007, 12:152-157.
18. Cooper Z.D., Shi Y.G., Woods J.H. Reinforcer-dependent enhancement of operant responding in opioid-withdrawn rats. Psychopharmacology 2010, 212:369-378.
19. Rouibi K., Contarino A. Increased motivation to eat in opiate-withdrawn mice. Psychopharmacology 2012, 221:675-684.
20. Anraku T., Ikegaya Y., Matsuki N., Nishiyama N. Withdrawal from chronic morphine administration causes prolonged enhancement of immobility in rat forced swimming test. Psychopharmacology 2001, 157:217-220.
21. Molina V.A., Heyser C.J., Spear L.P. Chronic variable stress or chronic morphine facilitates immobility in a forced swim test: reversal by naloxone. Psychopharmacology 1994, 114:433-440.
22. Grasing K., Ghosh S. Selegiline prevents long-term changes in dopamine efflux and stress immobility during the second and third weeks of abstinence following opiate withdrawal. Neuropharmacology 1998, 37:1007-1017.
23. Hodgson S.R., Hofford R.S., Wellman P.J., Eitan S. Different affective response to opioid withdrawal in adolescent and adult mice. Life Sciences 2009, 84:52-60.
24. Goeldner C., Lutz P.E., Darcq E., Halter T., Clesse D., Ouagazzal A.M., et al. Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. Biological Psychiatry 2011, 69:236-244.
25. Paus T., Keshavan M., Giedd J.N. Why do many psychiatric disorders emerge during adolescence. Nature Reviews Neuroscience 2008, 9:947-957.
26. Romeo R.D. Adolescence: a central event in shaping stress reactivity. Developmental Psychobiology 2010, 52:244-253.
27. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neuroscience and Biobehavioral Reviews 2000, 24:417-463.
28. Romeo R.D. Pubertal maturation and programming of hypothalamic-pituitary-adrenal reactivity. Frontiers in Neuroendocrinology 2010, 31:232-240.
29. Degenhardt L., Coffey C., Moran P., Carlin J.B., Patton G.C. The predictors and consequences of adolescent amphetamine use: findings from the Victoria Adolescent Health Cohort Study. Addiction 2007, 102:1076-1084.
30. Hayatbakhsh M.R., Najman J.M., Jamrozik K., Mamun A.A., Alati R., Bor W. Cannabis and anxiety and depression in young adults: a large prospective study. Journal of the American Academy of Child and Adolescent Psychiatry 2007, 46:408-417.
31. Rao U., Daley S.E., Hammen C. Relationship between depression and substance use disorders in adolescent women during the transition to adulthood. Journal of the American Academy of Child and Adolescent Psychiatry 2000, 39:215-222.
32. Doherty J., Ogbomnwan Y., Williams B., Frantz K. Age-dependent morphine intake and cue-induced reinstatement, but not escalation in intake, by adolescent and adult male rats. Pharmacology Biochemistry and Behavior 2009, 92:164-172.
33. Zhang Y., Picetti R., Butelman E.R., Schlussman S.D., Ho A., Kreek M.J. Behavioral and neurochemical changes induced by oxycodone differ between adolescent and adult mice. Neuropsychopharmacology 2009, 34:912-922.
34. Doherty J.M., Frantz K.J. Heroin self-administration and reinstatement of heroin-seeking in adolescent vs adult male rats. Psychopharmacology 2012, 219:763-773.
35. Somerville L.H., Jones R.M., Casey B.J. A time of change: behavioral and neural correlates of adolescent sensitivity to appetitive and aversive environmental cues. Brain and Cognition 2009, 72:124-133.
36. Yurgelun-Todd D. Emotional and cognitive changes during adolescence. Current Opinion in Neurobiology 2007, 17:251-257.
37. Matthes H.W., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996, 383:819-823.
38. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC. fourth edition.
39. Goeldner C., Reiss D., Kieffer B.L., Ouagazzal A.M. Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior. Hippocampus 2010, 20:911-916.
40. Wall P.M., Blanchard R.J., Yang M., Blanchard D.C. Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003, 27:395-410.
41. Mandillo S., Tucci V., Holter S.M., Meziane H., Banchaabouchi M.A., Kallnik M., et al. Reliability, robustness, and reproducibility in mouse behavioral phenotyping: a cross-laboratory study. Physiological Genomics 2008, 34:243-255.
42. Belzung C., Le Guisquet A.M., Crestani F. Flumazenil induces benzodiazepine partial agonist-like effects in BALB/c but not C57BL/6 mice. Psychopharmacology 2000, 148:24-32.
43. Akillioglu K., Melik E.B., Melik E., Boga A. Effect of ketamine on exploratory behaviour in BALB/C and C57BL/6 mice. Pharmacology Biochemistry and Behavior 2012, 100:513-517.
44. Tang X., Orchard S.M., Sanford L.D. Home cage activity and behavioral performance in inbred and hybrid mice. Behavioural Brain Research 2002, 136:555-569.
45. Bothe G.W., Bolivar V.J., Vedder M.J., Geistfeld J.G. Genetic and behavioral differences among five inbred mouse strains commonly used in the production of transgenic and knockout mice. Genes, Brain and Behavior 2004, 3:149-157.
46. Carola V., D'Olimpio F., Brunamonti E., Mangia F., Renzi P. Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behaviour in inbred mice. Behavioural Brain Research 2002, 134:49-57.
47. Hughes R.N. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neuroscience and Biobehavioral Reviews 2004, 28:497-505.
48. Kendler K.S., Prescott C.A., Myers J., Neale M.C. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Archives of General Psychiatry 2003, 60:929-937.
49. Goldman D., Oroszi G., Ducci F. The genetics of addictions: uncovering the genes. Nature Reviews Genetics 2005, 6:521-532.
50. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
51. Pothion S., Bizot J.C., Trovero F., Belzung C. Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress. Behavioural Brain Research 2004, 155:135-146.
52. Zhang X., Beaulieu J.M., Sotnikova T.D., Gainetdinov R.R., Caron M.G. Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science 2004, 305:217.
53. Kest B., Palmese C.A., Hopkins E., Adler M., Juni A., Mogil J.S. Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience 2002, 115:463-469.
54. Klein G., Juni A., Waxman A.R., Arout C.A., Inturrisi C.E., Kest B. A survey of acute and chronic heroin dependence in ten inbred mouse strains: evidence of genetic correlation with morphine dependence. Pharmacology Biochemistry and Behavior 2008, 90:447-452.
55. Szumlinski K.K., Lominac K.D., Frys K.A., Middaugh L.D. Genetic variation in heroin-induced changes in behaviour: effects of B6 strain dose on conditioned reward and locomotor sensitization in 129-B6 hybrid mice. Genes, Brain and Behavior 2005, 4:324-336.
56. Belzung C., Barreau S. Differences in drug-induced place conditioning between BALB/c and C57Bl/6 mice. Pharmacology Biochemistry and Behavior 2000, 65:419-423.
57. Bodnar R.J. Endogenous opiates and behavior: 2010. Peptides 2011, 32:2522-2552.
58. Matsuo N., Takao K., Nakanishi K., Yamasaki N., Tanda K., Miyakawa T. Behavioral profiles of three C57BL/6 substrains. Frontiers in Behavioral Neuroscience 2010, 4:29.
59. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nature Reviews Drug Discovery 2005, 4:775-790.
60. File S.E. Animal models of different anxiety states. Advances in Biochemical Psychopharmacology 1995, 48:93-113.
61. Rodgers R.J. Animal models of 'anxiety': where next?. Behavioural Pharmacology 1997, 8:477-496. [discussion 97-504].
62. Sankoorikal G.M., Kaercher K.A., Boon C.J., Lee J.K., Brodkin E.S. A mouse model system for genetic analysis of sociability: C57BL/6J versus BALB/cJ inbred mouse strains. Biological Psychiatry 2006, 59:415-423.
63. Moy S.S., Nadler J.J., Young N.B., Perez A., Holloway L.P., Barbaro R.P., et al. Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains. Behavioural Brain Research 2007, 176:4-20.
64. Dulawa S.C., Holick K.A., Gundersen B., Hen R. Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 2004, 29:1321-1330.
65. Liu X., Gershenfeld H.K. Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice. Biological Psychiatry 2001, 49:575-581.
66. Norcross M., Mathur P., Enoch A.J., Karlsson R.M., Brigman J.L., Cameron H.A., et al. Effects of adolescent fluoxetine treatment on fear-, anxiety- or stress-related behaviors in C57BL/6J or BALB/cJ mice. Psychopharmacology 2008, 200:413-424.
67. Buckman S.G., Hodgson S.R., Hofford R.S., Eitan S. Increased elevated plus maze open-arm time in mice during spontaneous morphine withdrawal. Behavioural Brain Research 2009, 197:454-456.
68. Harris G.C., Aston-Jones G. Augmented accumbal serotonin levels decrease the preference for a morphine associated environment during withdrawal. Neuropsychopharmacology 2001, 24:75-85.
69. Grasing K., Wang A., Schlussman S. Behavioral measures of anxiety during opiate withdrawal. Behavioural Brain Research 1996, 80:195-201.
70. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacology Biochemistry and Behavior 2005, 81:319-330.
71. Fishbein D.H., Krupitsky E., Flannery B.A., Langevin D.J., Bobashev G., Verbitskaya E., et al. Neurocognitive characterizations of Russian heroin addicts without a significant history of other drug use. Drug and Alcohol Dependence 2007, 90:25-38.
72. Itoh J., Ukai M., Kameyama T. Dynorphin A-(1-13) potently improves the impairment of spontaneous alternation performance induced by the mu-selective opioid receptor agonist DAMGO in mice. Journal of Pharmacology and Experimental Therapeutics 1994, 269:15-21.
73. Ma M.X., Chen Y.M., He J., Zeng T., Wang J.H. Effects of morphine and its withdrawal on Y-maze spatial recognition memory in mice. Neuroscience 2007, 147:1059-1065.
74. Talley C.P., Arankowsky-Sandoval G., McCarty R., Gold P.E. Attenuation of morphine-induced behavioral changes in rodents by d- and l-glucose. Neurobiology of Learning and Memory 1999, 71:62-79.
75. Ukai M., Watanabe Y., Kameyama T. Effects of endomorphins-1 and -2, endogenous mu-opioid receptor agonists, on spontaneous alternation performance in mice. European Journal of Pharmacology 2000, 395:211-215.
76. Moles A., Kieffer B.L., D'Amato F.R. Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. Science 2004, 304:1983-1986.
77. Barr C.S., Schwandt M.L., Lindell S.G., Higley J.D., Maestripieri D., Goldman D., et al. Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:5277-5281.
78. Copeland W.E., Sun H., Costello E.J., Angold A., Heilig M.A., Barr C.S. Child mu-opioid receptor gene variant influences parent-child relations. Neuropsychopharmacology 2011, 36:1165-1170.
79. Ladd G.W. Peer relationships and social competence during early and middle childhood. Annual Review of Psychology 1999, 50:333-359.
80. Depue R.A., Morrone-Strupinsky J.V. A neurobehavioral model of affiliative bonding: implications for conceptualizing a human trait of affiliation. Behavioral and Brain Sciences 2005, 28:313-350. [discussion 50-95].
81. Van den Berg C.L., Kitchen I., Gerrits M.A., Spruijt B.M., Van Ree J.M. Morphine treatment during juvenile isolation increases social activity and opioid peptides release in the adult rat. Brain Research 1999, 830:16-23.
82. Trezza V., Baarendse P.J., Vanderschuren L.J. The pleasures of play: pharmacological insights into social reward mechanisms. Trends in Pharmacological Sciences 2010, 31:463-469.
83. Panksepp J.B., Lahvis G.P. Social reward among juvenile mice. Genes, Brain and Behavior 2007, 6:661-671.
84. Panksepp J.B., Wong J.C., Kennedy B.C., Lahvis G.P. Differential entrainment of a social rhythm in adolescent mice. Behavioural Brain Research 2008, 195:239-245.
85. Trezza V., Damsteegt R., Achterberg E.J., Vanderschuren L.J. Nucleus accumbens {micro}-opioid receptors mediate social reward. The Journal of Neuroscience 2011, 31:6362-6370.
86. Meyer-Lindenberg A., Domes G., Kirsch P., Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nature Reviews Neuroscience 2011, 12:524-538.
87. Morris M.S., Domino E.F., Domino S.E. Opioid modulation of oxytocin release. Journal of Clinical Pharmacology 2010, 50:1112-1117.
88. Honda K., Takano Y. New topics in vasopressin receptors and approach to novel drugs: involvement of vasopressin V1a and V1b receptors in nociceptive responses and morphine-induced effects. Journal of Pharmacological Sciences 2009, 109:38-43.
89. Lutz P.E., Pradhan A.A., Goeldner C., Kieffer B.L. Sequential and opposing alterations of 5-HT(1A) receptor function during withdrawal from chronic morphine. European Neuropsychopharmacology 2011, 21:835-840.
90. Schramm-Sapyta N.L., Walker Q.D., Caster J.M., Levin E.D., Kuhn C.M. Are adolescents more vulnerable to drug addiction than adults Evidence from animal models. Psychopharmacology 2009, 206:1-21.
91. Koek W., France C.P., Javors M.A. Morphine-induced motor stimulation, motor incoordination, and hypothermia in adolescent and adult mice. Psychopharmacology 2012, 219:1027-1037.
92. Carretero J., Bodego P., Rodriguez R.E., Rubio M., Blanco E., Burks D.J. Expression of the mu-opioid receptor in the anterior pituitary gland is influenced by age and sex. Neuropeptides 2004, 38:63-68.
93. Gazyakan E., Disko U., Haaf A., Heimrich B., Jackisch R. Postnatal development of opioid receptors modulating acetylcholine release in hippocampus and septum of the rat. Brain Research Developmental Brain Research 2000, 123:135-141.
94. Talbot J.N., Happe H.K., Murrin L.C. Mu opioid receptor coupling to Gi/o proteins increases during postnatal development in rat brain. Journal of Pharmacology and Experimental Therapeutics 2005, 314:596-602.
95. De Vries T.J., Hogenboom F., Mulder A.H., Schoffelmeer A.N. Ontogeny of mu-, delta- and kappa-opioid receptors mediating inhibition of neurotransmitter release and adenylate cyclase activity in rat brain. Brain Research Developmental Brain Research 1990, 54:63-69.
96. Adamson W.T., Windh R.T., Blackford S., Kuhn C.M. Ontogeny of mu- and kappa-opiate receptor control of the hypothalamo-pituitary-adrenal axis in rats. Endocrinology 1991, 129:959-964.
97. Blackford S.P., Little P.J., Kuhn C.M. Mu- and kappa-opiate receptor control of prolactin secretion in rats: ontogeny and interaction with serotonin. Endocrinology 1992, 131:2891-2897.
98. Tavani A., Robson L.E., Kosterlitz H.W. Differential postnatal development of mu-, delta-and chi-opioid binding sites in mouse brain. Brain Research 1985, 355:306-309.
99. Barg J., Rius R.A., Bem W.T., Belcheva M.M., Loh Y.P., Coscia C.J. Differential development of beta-endorphin and mu opioid binding sites in mouse brain. Brain Research Developmental Brain Research 1992, 66:71-76.